In particular, PPARα plays a role in both MASLD and ALD; its expression is negatively correlated with NASH severity, and treatment with a PPARα agonist reverses abnormalities in ethanol-fed mice [34,35]. Here, PPARA is linked to metabolic dysfunction-associated steatohepatitis.